Analyst Ratings for Ambrx Biopharma
Portfolio Pulse from Benzinga Insights
Ambrx Biopharma (NASDAQ:AMAM) has received 7 analyst ratings in the last quarter with an average price target of $23.71, which is significantly higher than its current price of $8.88. The consensus among analysts appears to be positive, with 1 bullish and 5 somewhat bullish ratings. The average price target has increased by 4.59% from the previous target of $22.67.
November 14, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ambrx Biopharma has a positive outlook from analysts with an average price target of $23.71, indicating a potential significant upside from the current price of $8.88.
The positive analyst ratings and the increased average price target suggest that there is a strong belief in the potential growth of Ambrx Biopharma. This optimism is likely to influence investor sentiment and could lead to a short-term increase in the stock price, especially considering the significant gap between the current price and the target.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100